The kidney is the main physiologic source of erythropoietin (EPO) in the adult, and responds to changes in tissue oxygenation with increased EPO production. Although studies in mice with liver-specific or global gene inactivation have shown that hypoxiainducible factor (Hif)-2 plays a major role in the regulation of Epo during infancy and in the adult respectively, the contribution of renal HIF-2 signaling to systemic EPO homeostasis, and the role of extra-renal HIF-2 in erythropoiesis, in the absence of kidney EPO, has not been examined directly. Here, we used Cre-loxP recombination to ablate Hif-2α in the kidney, while Hif-2-mediated hypoxia responses in the liver and other Epoproducing tissues remained intact. We found that the hypoxic induction of renal Epo is completely Hif-2-dependent, and that in the absence of renal Hif-2, hepatic Hif-2 takes over as the main regulator of serum Epo levels. Furthermore, we provide evidence that hepatocyte-derived Hif-2 is involved in the regulation of iron metabolism genes, supporting a role for HIF-2 in the coordination of EPO synthesis with iron homeostasis.
Introduction
The glycoprotein erythropoietin (EPO) is essential for the regulation of red blood cell mass in response to changes in tissue oxygenation. EPO stimulates erythropoiesis by promoting erythroid precursor cell viability, proliferation, and differentiation, thus enhancing the oxygen-carrying capacity of blood. Its production is tightly regulated by developmental, tissue-specific, and physiologic cues 1, 2 . Lack of Epo in the embryo, where it is produced by hepatocytes, leads to death from cardiac failure and anemia at embryonic day (E) 13.5 3 . During late gestation, the site of EPO production switches from the fetal liver to the kidney, where fibroblast-like peri-tubular interstitial cells become the main physiologic source of EPO synthesis in adults [4] [5] [6] . Although the liver retains the ability to produce EPO in response to hypoxic stimuli, it does not contribute to the serum EPO pool under normoxic or mild hypoxic conditions [7] [8] [9] . Therefore, an impairment of renal EPO synthesis, which is typically associated with advanced chronic kidney failure, results in the development of anemia, and is treated by administration of recombinant EPO 2, 10 .
The primary physiologic stimulus of enhanced EPO gene transcription is tissue hypoxia, which can induce a several hundred-fold increase in circulating serum EPO levels 1 . Although in vitro studies, utilizing an 18 nucleotide fragment of the oxygensensitive 3' EPO regulatory element, suggested that hypoxia inducible factor-1 (HIF-1)
regulates EPO in Hep3B cells [11] [12] [13] , recent genetic evidence indicates that Hif-2 has an important role in the maintenance of normal serum EPO levels [14] [15] [16] . HIF-1 and HIF-2 belong to the PAS {PER/aryl-hydrocarbon-receptor nuclear translocator (ARNT)/single minded (SIM)} family of hypoxia-regulated transcription factors, and consist of an
For personal use only. on April 5, 2017 . by guest www.bloodjournal.org From oxygen-sensitive α-subunit and a constitutively expressed β-subunit, also known as ARNT (arylhydrocarbon receptor nuclear translocator). Both factors facilitate oxygen delivery and cellular adaptation to hypoxia by stimulating erythropoiesis, angiogenesis, and anaerobic glucose metabolism. Under normoxia, HIF-1α and HIF-2α are targeted for rapid proteasomal degradation by the von Hippel-Lindau tumor suppressor, pVHL, which functions as the substrate recognition component of an E3 ubiquitin ligase. pVHLmediated targeting of HIF-α requires oxygen-and iron-dependent hydroxylation of specific proline residues within the oxygen-dependent degradation domain (ODD) of HIF-α, carried out by prolyl-4-hydroxylase domain (PHD) proteins (for a recent review on this topic 17 ).
Even though HIF-1 was initially purified from Hep3B cells, use of small interfering
RNAs directed against individual HIF-α homologs demonstrated that the hypoxic induction of endogenous EPO was largely HIF-2-dependent in Hep3B and other cell lines 18, 19 . The notion that HIF-2 acts as a main regulator of EPO homeostasis in vivo, is based on histological studies, which demonstrated that the location of Epo-producing renal interstitial fibroblast-like cells coincided with the location of Hif-2α-expressing renal cells 20 , and on genetic studies with adult mice that were either germ line deficient for Hif-2, or that were made Hif-2-deficient during postnatal life using a ubiquitously expressed Cre-recombinase 14, 16 . The latter study furthermore showed that widespread postnatal ablation of Hif-1α, did not result in anemia, which is in contrast to studies with mice that were heterozygously deficient for Hif-1α 21, 22 . Global knock out of Phd2, however, suggested that Hif-1 rather than Hif-2 contributed to increased renal Epo synthesis, as Hif-2α was not detectable in Phd2-deficient kidneys, and did not clarify the To specifically investigate the role of renal HIF-2 in the regulation of serum EPO homeostasis, and to examine the contribution of non-renal HIF-signaling in the absence of hypoxically induced renal EPO, we used Cre-loxP recombination to inactivate Hif-2α in the kidney, while Hif-2-mediated hypoxia responses in the liver and other organs remained intact. Our data establish that the hypoxic induction of Epo in the kidney is exclusively dependent on Hif-2, and that in the absence of renal Hif-2, hepatic Hif-2 takes over as the main regulator of the serum Epo pool. Furthermore, we show that the Epo-producing capability of the liver can be exploited therapeutically, when the kidney, the main physiologic source of Epo in the adult, fails to respond to hypoxia with an appropriate increase in Epo synthesis.
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Materials and Methods
Generation of mice and genotyping. The generation and genotyping of Hif1a, Hif2a (Epas1), and Vhlh conditional alleles, and P3Pro-and Albumin-Cre transgenes have been described previously 14, [24] [25] [26] [27] [28] . In P3Pro-Cre transgenic mice, which were generated by pronuclear injection, Cre recombinase expression is under the control of the murine Pax3 promoter and is active in neural crest-derived cells and in renal epithelial and interstitial cells 26 . The Albumin-Cre transgene utilizes a 2.35 Kb fragment from the rat albumin enhancer/promoter and targets at least 80-90% of hepatocytes by 6 weeks of age 24, 27, 28 . All procedures involving mice were performed in accordance with NIH Hypoxia experiments: Mice were exposed to 10% O 2 for 10 days in an animal hypoxia chamber (Biospherix Ltd, NY) and analyzed immediately following exposure. Anemic hypoxia was generated in anaesthetized mice by retro-orbital phlebotomy or by a combination of phlebotomy with phenylhydrazine treatment as previously described 15 . 
Stabilization of HIF-α by prolyl-4-hydroxylase inhibitor or

Results
Generation of conditional knock out mice with Hif-2α inactivation in the kidney
To investigate the role of renal HIF-2 in the regulation of serum EPO levels, P3Pro-Cre transgenic mice were crossed to mice homozygous for the conditional Hif-2α allele 14, 26 . Recombination of the conditional Hif-2α allele was highly efficient in kidneys as determined by genomic PCR (> 95%, data not shown). This is reflected in an almost complete reduction of Hif-2α exon 2 transcript levels (exon 2 is flanked by loxP sites and targeted for Cre-mediated recombination, Figure 1A ). Although recombination was detectable in liver DNA, we did not find a significant difference in the expression levels of Hif-2α exon 2 between mutant and control livers ( Figure 1A ). As shown in Figure 1B Bone marrow responsiveness to recombinant EPO was normal in P3Pro mutants (Supplemental Figure S1C ). Taken together, these studies show that Hif-2α was ablated in the majority of renal cells, whereas loss of Hif-2α in a small percentage of hepatocytes did not significantly affect Hif-2-mediated hypoxia responses in the liver.
Inactivation of renal Hif-2α results in hypoproliferative anemia
P3Pro mutants were born in Mendelian ratios and developed normally. While males were fertile, female mutants were not able to generate offspring. The paws of mutant mice were pale, and peripheral blood smears were consistent with normochromic, normocytic anemia. Complete blood count (CBC) analysis at ages 2 to 5 months demonstrated that red blood cell (RBC) numbers and hematocrit (Hct) values were substantially reduced in P3Pro mutants ( Figure 2A and data not shown). In mutant mice (n=26) mean RBC counts and Hct levels were 5.27 ± 0.12 x 10 6 /μl and 24 ± 0.6% respectively compared to 9.89 ± 0.19 x 10 6 /μl and 46 ± 1.0% in control mice (n=21).
Despite the lower RBC counts, reticulocyte percentages in mutants did not differ from littermate controls and were 2.5% and 2.6% respectively, which is consistent with hypoproliferative anemia. Deficits in non-erythroid hematopoietic lineages were not present, as numbers of white blood cells (7.9 ± 0.7 x 10 6 /μl) and platelets (935 ± 53 x 10 6 /μl) were within normal limits. This is in contrast to mice with Hif-2α germ line inactivation, which developed pancytopenia 16 . Serum iron levels and total iron binding capacity (TIBC) were not different between P3Pro mutants and littermate controls excluding iron deficiency as contributing cause of anemia (Supplemental Figure S1A ).
Since advanced renal failure is frequently associated with anemia, we assessed kidney
For personal use only. on April 5, 2017 . by guest www.bloodjournal.org From function in mutant mice. Blood urea nitrogen (BUN) and serum creatinine levels were comparable between mutants and controls, and kidneys from mutant mice were histologically normal at 3 months of age, which excludes renal disease as a cause of the anemia (Supplemental Figure S1B) . Next, we investigated to which degree targeted deletion of Hif-2α in the kidney affected serum Epo levels. We found that despite the presence of anemia, serum Epo levels were significantly lower in mutant mice compared to controls (116 ± 12 pg/ml and 166 ± 9 pg/ml respectively; p<0.01; Figure 2B ), and that Epo mRNA in mutant kidneys was decreased by approximately 12-fold (P<0.001; Figure 2C ). The anemia in mutant mice was furthermore associated with increased levels of renal Hif-1α, and increased expression of HIF target genes Glut1, Pkg, Ldha and Phd3 ( Figure 2D , Supplemental Figure S2C and data not shown), indicating the presence of hypoxia. Despite the activation of Hif-1 signaling, mutant kidneys did not respond to anemia with increased Epo production, suggesting that the hypoxic regulation of EPO in the kidney is not HIF-
1-dependent.
Hepatic Epo synthesis is not suppressed in P3Pro mutant mice
Since the main source of EPO changes from the liver to the kidney perinatally, we investigated whether lack of renal Hif-2 had any effect on the developmental switch in tissue Epo expression. PCR-analysis of genomic DNA isolated from mutant kidney extracts at different time points after birth indicated comparable recombination efficiency at postnatal days (P) 2, 10, 20 and 90 (Supplemental Figure S1D) . Whereas renal Epo mRNA levels were substantially suppressed at P10, P20 and P90, hepatic Epo in mutant mice did not decline at P10, P20 and P90 compared to littermate control mice, where it became undetectable at P20 and P90 using real-time PCR (Figure 3 ; n=6; P<0.05).
Interestingly, renal Epo mRNA levels at P2 did not differ between mutants and controls, suggesting that the regulation of Epo expression at this stage of postnatal development may be Hif-2-independent.
Hypoxic stimulation of erythropoiesis in P3Pro mutants is kidney-independent
Renal EPO synthesis is stimulated in a graded manner by changes in tissue pO 2 1, 2 .
To further investigate the relative contribution of renal Hif-2 to Epo synthesis in P3Pro mutants, mice were either challenged with acute or chronic hypoxia, or were treated with HIF-stabilizing agents. Acute anemic hypoxia was induced by phlebotomy in P3Pro mutants and serum Epo levels were compared to littermate controls with similar Hcts. A linear decrease in Hct was associated with an exponential increase in serum Epo levels in both wild type animals and in P3Pro mutants ( Figure 4A , R 2 =0.60, P<0.001 for mutants) 30 . The slopes of increase were similar in P3Pro mutants and in wild type mice ( Figure   4A ). To determine to what degree chronic hypoxia was able to trigger erythropoietic responses in P3Pro mutants, mice were subjected to normobaric hypoxia (10% O 2 ) for 10 days. Hcts rose from a mean of 23 ± 1.3% to 41 ± 0.8% in P3Pro mutants, and from 49 ± 1.5% to 65 ± 3.6% in Cre-negative controls ( Figure 4B ). While increases in serum Epo levels were found in both groups, mutants generated 2-fold less serum Epo ( Figure 4B ).
The time course of this response was similar between mutants and controls; serum Epo levels peaked at day 3-5 and remained elevated even after 4 weeks of exposure (data not shown). HIF prolyl-4-hydroxylase inhibitors (PHI) have previously been shown to induce erythropoiesis by enhancing endogenous EPO production 31 . To further examine the erythropoietic response following systemic HIF-stabilization under normoxic conditions, P3Pro mutants were treated with GSK1002083A, which stabilizes both Hif-1α and Hif-2α in vitro and in vivo, and has been shown to induce erythrocytosis in wild type mice (Supplemental Figure S2A ; Figure 4C ). Mutants were treated by daily oral gavage for a period of 10 days. After completion of treatment, Hct values increased from 24 ± 1% to 35 ± 1% in mutants, while Hcts in vehicle-treated mice did not change ( Figure 4C ). The increase in Hct following PHI treatment was associated with a substantial rise in serum Epo levels 4 hours after drug administration (3564 ± 1041 pg/ml vs. 98 ± 4 pg/ml in vehicle-treated mice; Figure 4C ). Similarly to chronic hypoxia, mutants generated less serum Epo than wild type controls (Supplemental Figure S2A , lower panel). Whereas both Hif-1α and Hif-2α were stabilized in wild type kidneys, Hif-2α was not detectable in mutant kidneys, which is consistent with the high recombination efficiency of the conditional Hif-2α allele (Supplemental Figure S2B) .
HIF target genes
Ldha and Pgk were significantly induced by PHI treatment in both, mutant and wild type kidneys (Supplemental Figure S2C ). Our data demonstrate that mice, which lack renal Hif-2α have the ability to respond to hypoxic stimuli and to systemic HIF prolyl-4-hydroxylase inhibition with increased erythropoiesis.
We next investigated whether renal Epo synthesis was stimulated in P3Pro mutants subjected to hypoxia or PHI treatment. We found that, despite up-regulation of HIF target genes (Supplemental Figure S2C) , Epo mRNA in Hif-2-deficient kidneys was neither induced by hypoxia nor by treatment with GSK1002083A or cobalt chloride ( Figure 5 and data not shown). Since the liver is the primary site of extra-renal EPO
production in hypoxic adults, we next examined whether Epo mRNA in the liver was significantly induced. Expression levels of hepatic Epo in mutants were similar to anemic wild type mice with comparable Hcts, suggesting that the liver Epo response to tissue hypoxia was not enhanced in the absence of renal Hif-2 ( Figure 6A ). Furthermore, we found that, following acute anemic hypoxia, the linear decline in Hct was associated with a logarithmic increase in hepatic Epo mRNA levels (R 2 =0.61, P<0.01), qualitatively resembling the renal Epo response in wild type animals ( Figure 6A ). In keeping with this observation, exposure to 10 days of hypoxia or PHI administration led to a ~15-and ~1500-fold increase in hepatic Epo mRNA levels respectively ( Figure 6B and C). In summary, our findings demonstrate that in adult mice Hif-2 is required for the hypoxiainducibility of Epo in the kidney, and that in the absence of renal Hif-2, hypoxic stimulation of erythropoiesis is associated with increased hepatic Epo transcription.
Furthermore, our data indicate that Hif-1 in adults does not participate in the renal Epo reponse to hypoxia or to PHD inhibition.
Hepatocyte-derived Hif-2 regulates erythropoiesis in P3Pro mutants
Although hepatocytes have been shown to be the main site of extrarenal EPO production under hypoxia, EPO is also expressed in other organs such as brain, spleen, lung, testis and uterus 1 . To specifically investigate the role of hepatocyte-derived Hif-2 in the hypoxia-stimulated erythropoietic response of P3Pro mutants, we generated Hif-2α conditional knock out mice, that lack Hif-2α in the kidney and in hepatocytes, by crossing Alb-Cre transgenic mice with P3Pro mutants, which are from hereon referred to as Alb/P3Pro double mutants. Alb/P3Pro double mutant mice were born at half the Figure 7A ). The reduction in Hgb in double mutants was associated with decreased serum Epo concentrations (124 ± 2 vs. 148 ± 8 pg/ml, P<0.05; Figure   7A ), suggesting that hepatic Hif-2 contributes to the regulation of the serum Epo levels in P3Pro mutants under baseline conditions.
In order to examine hypoxia-triggered erythropoietic responses in Alb/P3Pro double mutants, mice were challenged with acute anemic hypoxia induced by phlebotomy.
Alb/P3Pro mutants exhibited an approximately 70% reduction in serum Epo levels compared to P3Pro mutants (1535 + 612 pg/ml and 465 + 72 pg/ml, respectively; P<0.05), which was associated with a corresponding decrease in liver Epo mRNA levels ( Figure 7B ). These data suggest that under these conditions at least 70% of serum Epo is generated through the activation of hepatocyte-derived Hif-2 signaling. Moreover, our experiments most likely underestimate Hif-2's contribution due to limitations in recombination efficiency, as not all hepatocytes express the Albumin-Cre transgene.
Consistent with the findings under acute hypoxia are the results from chronic hypoxia exposure (10% O 2 x 10 days), where serum Epo levels in Alb/P3Pro mutants were reduced by approximately 60% (281 + 37 pg/ml, compared to 122 + 15 pg/ml in P3Pro mice; P<0.05; Figure 7C ). The difference in hepatic Epo mRNA expression under chronic hypoxia, however, did not reach statistical significance (P=0.08). This is most likely due to sub-maximal hypoxic stimulation in this setting, which when compared to acute anemia resulted in lower liver Epo output (for P3Pro mutants 281 + 37 pg/ml vs. 1535 + 612 pg/ml) and would require a larger sample size to detect statistically For personal use only. on April 5, 2017. by guest www.bloodjournal.org From significant differences. Nevertheless, taken together, our results suggest that under acute hypoxic conditions hepatocyte-derived Hif-2 regulates at least 70% of the serum Epo pool and appears to be the main regulator of serum Epo in the absence of renal Hif-2.
Hif-2-dependent regulation of iron metabolism genes
Hypoxic stimulation of erythropoiesis requires that additional iron is readily made available for heme-synthesis. Since the liver plays a central role in the regulation of iron homeostasis, we hypothesized that HIF-2 may coordinate EPO production with iron metabolism in the liver. We therefore examined to what degree hepatocyte-derived Hif-2 participated in the hypoxic regulation of genes involved in iron metabolism. To address this question we made use of two different models of Hif activation. In the first model, non-hypoxic Hif stabilization was accomplished by cell type-specific pVHL inactivation in hepatocytes, in the second model, Hif was stabilized by systemic hypoxia in all liver cells. We first determined mRNA levels of iron metabolism genes in littermate control mice, Albumin-Cre/Vhlh mutant mice (Vhlh is the symbol for murine VHL), which express both Hif-1α and Hif-2α in hepatocytes, Albumin-Cre/Vhlh/Hif-1α mutants, which lack Hif-1α and express Hif-2α in hepatocytes, Albumin-Cre/Vhlh/Hif-2α mice, which only express Hif-1α, and Albumin-Cre/Vhlh/Hif-1α/Hif-2α mutants, which lack both Hifs in hepatocytes. We found a Hif-2-dependent increase in the expression levels of ceruloplasmin (Cp), hephaestin (Heph), delta-aminolevulinate synthase 2 (Alas2), divalent metal transporter 1 (Dmt1), mitoferrin (Mfrn), transferrin (Trf) . Iron metabolism gene expression in whole liver homogenates was examined by real-time PCR in anemic mice (Hct levels of ~15%), which expressed both Hif-1 and Hif-2 in the liver, and in anemic mice, which either lacked Hif-1α (Albumin-Cre/Hif-1α), Hif-2α (Albumin-Cre/Hif-2α) or both (AlbuminCre/Hif-1α/Hif-2α) in hepatocytes specifically. mRNA levels were compared to normocythemic Cre-negative control mice 15 . Using this model, we identified Dmt1 as being co-regulated by hepatocyte-derived Hif-1 and Hif-2 in a statistically significant manner, whereas the expression levels of other hypoxia-induced genes in the liver, were not strongly affected by Hif inactivation in hepatocytes (Supplementary Table S2 and
Supplementary Figure S4 ). Our data indicate that in a pVHL-deficient background iron metabolism gene expression in hepatocytes is predominantly Hif-2-regulated.
Discussion
In this report we have used a genetic approach to a) specifically investigate the role of renal HIF-2 in the regulation of serum EPO levels and b) to examine the degree by which non-renal HIF-2 contributes to hypoxia-stimulated erythropoiesis.
Our data, which demonstrate that renal Epo is exclusively Hif-2-regulated, are compatible with immunohistochemical studies that localized Hif-2α but not Hif-1α to For personal use only. on April 5, 2017 . by guest www.bloodjournal.org From P3Pro mutants lack hypoxia-inducibility of renal Epo completely, whereas their hepatic Epo response is normal. While the kidney is the primary physiologic site of postnatal EPO synthesis, the liver is the main source during embryonic development and produces EPO in adults only under severe hypoxic conditions. Although hepatocytes are the primary EPO-expressing cell type in the liver, Epo has been detected in hepatic stellate cells, which are also known as Ito cells 36, 37 . The timing of transition from the liver to the kidney as the primary site of EPO production is species-dependent, and usually occurs late in gestation or around birth 7, [38] [39] [40] . The molecular mechanisms that control this switch are poorly understood and may involve transcriptional repression and/or reduced expression of transcriptional activators such as GATA-4 41 . However, we found that hepatic Gata-4 mRNA levels were not different between P3Pro mutants and controls, suggesting that increased Gata-4 levels are not required for persistent hepatic Epo expression found in mutant mice (data not shown). Since the onset of the transition from liver to kidney as the main EPO source was significantly delayed in chronically anemic sheep 38 , it is likely that liver pO 2 plays a major role in the regulation of this transition.
We found that hepatocyte-derived Hif-2 is the main regulator of serum Epo in the absence of hypoxia-inducible renal Epo, as serum Epo levels were reduced by approximately 60-70% in hypoxic P3Pro/Albumin double mutants. It is likely that our study underestimated the contribution of hepatocyte-derived Hif-2 to the serum Epo pool, as only 80-90% of hepatocytes were targeted by the Albumin-Cre transgene. However, we cannot exclude that Ito cells or other organs have contributed to serum Epo levels in P3Pro/Albumin mutants. Recent studies proposed a significant role for glial Hif-2 in
For personal use only. on April 5, 2017. by guest www.bloodjournal.org From hypoxia-triggered erythropoiesis, suggesting that the brain can drive up to 50% of the erythropoietic response in acutely hypoxic mice 42 .
Inactivation of glial Hif-2α in P3Pro mutants using GFAP-Cre 43 , however, did not produce an additional decrease in Hct or serum Epo in response to acute anemic hypoxia (data not shown). EPO mRNA has also been detected in lung, testis, and uterus and in other cell types 1 , nevertheless the contribution of these sites to systemic EPO homeostasis appears to be negligible 7, 8 . The liver is the main source of extrarenal EPO and has the capacity to generate between 25 to 50% of circulating EPO under moderate to severe hypoxic conditions 7, 8 . Furthermore the lack of a significant rise in serum Epo under hypoxic conditions in animals that underwent bilateral nephrectomy combined with subtotal hepatectomy suggests that other organs do not contribute to the serum EPO pool 7, 9, 44 . Nevertheless, the ability of other sites to synthesize EPO can lead to polycythemia in certain pathological settings, e.g. in patients with uterine myomata or cerebellar hemangioblastomas 45, 46 .
The role of HIF-2 in hypoxia-induced erythropoiesis extends beyond the transcriptional control of EPO. Here, we also provide evidence that hepatocyte-derived Hif-2 is involved in the transcriptional regulation of several iron metabolism genes 47 .
When erythropoiesis is stimulated by hypoxia, iron demand in the bone marrow increases. This necessitates enhanced intestinal iron uptake, an augmentation of serum iron binding capacity and mobilization from body iron stores. We found that in a model of non-hypoxic constitutive Hif activation in hepatocyte-specific pVHL knock out mice, genes involved in iron homeostasis, such as Dmt1, ceruloplasmin and hephaestin are regulated by Hif-2, suggesting that hepatocyte-derived HIF-2 coordinates EPO synthesis with iron metabolism. This notion is supported by the recent observation that Hif-2
For personal use only. on April 5, 2017. by guest www.bloodjournal.org From regulates enteral iron-uptake through induction of intestinal Dmt-1 and DcytB 48, 49 . However, we were unable to establish an extensive role for hepatocyte-derived Hif-2 in iron metabolism using a model of anemic hypoxia. While Dmt1 appeared to be coregulated by Hif-1 and Hif-2, the hypoxic induction of other genes, such as ceruloplasmin, did not depend on hepatocyte-derived Hif in our analysis. This may be due to the use of whole liver homogenates and the contribution of other liver cell types to the RNA pool that was analyzed.
Pharmacologic HIF stabilization induced hepatic Epo mRNA levels and resulted in increased hemoglobin levels and anemia improvement in P3Pro mutants. Clinically, an impairment of the kidney's ability to synthesize adequate amounts of EPO is typically found in patients with chronic kidney disease (CKD), resulting in renal anemia 10 .
Although the VHL/PHD/HIF pathway appears to be operational in EPO-producing renal cells, EPO synthesis in the kidney is inadequate in this setting. The liver, which may also be negatively affected by uremia, only partially compensates for this impairment in renal EPO production 
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